Latest Us Expansion News

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

AML3D Limited closed FY26 with a record $29 million order book, driven by US defence contracts and a $12 million investment to double its Ohio manufacturing capacity. The company’s cash receipts rose 20% to $10.4 million, while its sales pipeline expanded to $78 million.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.

Iondrive appoints ex-BHP innovation chief Dr Grant Caffery as CEO, signalling a pivot from development to commercial scale-up following strong rare earth recovery results and a US$15 million Oklahoma funding pathway.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

Boresight Ltd has secured a lease for a new 812 square metre manufacturing hub in Huntsville, Alabama, vastly expanding its US production capacity for aerial target drones amid rising military demand.

Cyclopharm has landed a major US expansion deal with University Hospitals Cleveland, deploying Technegas® across 11 sites simultaneously and boosting its recurring revenue base in the Midwest.

HeraMED's Phase 1 pilot with Lee Health confirms strong patient adoption and operational efficiency for its digital maternity care platform, setting the stage for broader US rollout.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.